Tech Center 1600 • Art Units: 1636 1654
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17767663 | MODIFIED HETERO NUCLEIC ACIDS | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18273685 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17433639 | CIRCULAR POLYRIBONUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 17262591 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS VI, LLC |
| 18258909 | A PLASMID FOR TRANSFORMATION, A METHOD FOR PRODUCING A TRANSFORMANT USING THE SAME AND A METHOD OF TRANSFORMATION | Non-Final OA | TOYOTA JIDOSHA KABUSHIKI KAISHA |
| 18258799 | A HELPER PLASMID FOR TRANSFORMATION, A METHOD FOR PRODUCING A TRANSFORMANT USING THE SAME, AND A METHOD OF TRANSFORMATION | Non-Final OA | TOYOTA JIDOSHA KABUSHIKI KAISHA |
| 19092488 | MICROORGANISMS AND USES THEREOF | Final Rejection | United Kingdom Research and Innovation |
| 18275146 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 17332509 | Methods for Promoting Reinnervation of Auditory Hair Cells | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 18255645 | A HIGHLY SENSITIVE HEAT-REPRESSIBLE SPLIT-T7 POLYMERASE (THERMAL-T7RNAP) FOR APPLICATIONS IN BIOTECHNOLOGY | Non-Final OA | National University of Singapore |
| 17270711 | The Microbiome as a Target of MicroRNAs for the Treatment of Disease | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 17494047 | COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLUX CONTROL USING SYNTHETIC METABOLIC VALVES | Final Rejection | DUKE UNIVERSITY |
| 18278260 | INDUCIBLE SINGLE AAV SYSTEM AND USES THEREOF | Non-Final OA | University of Massachusetts |
| 17439025 | MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER | Final Rejection | The Research Foundation for The State University of New York |
| 18035573 | COMPOSITIONS AND METHODS FOR MODIFYING BACTERIAL GENE EXPRESSION | Non-Final OA | The Penn State Research Foundation |
| 17802751 | ACTIVATION OF LYTIC GENES IN CANCER CELLS | Final Rejection | The Chinese University of Hong Kong |
| 17945060 | METHODS FOR USING GUIDE RNAS WITH CHEMICAL MODIFICATIONS | Non-Final OA | Agilent Technologies, Inc. |
| 18769446 | NUCLEOTIDE AND USE THEREOF | Non-Final OA | GUANGZHOU REFORGENE MEDICINE CO., LTD. |
| 17608328 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF PF-ILD AND IPF | Non-Final OA | Boehringer Ingelheim International GmbH |
| 17269229 | OLIGONUCLEOTIDE INHIBITORS OF NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS AND THE USES THEREOF | Non-Final OA | City of Hope |
| 18278498 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | Non-Final OA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY |
| 17439344 | PRODUCTION OF dsRNA IN PLANT CELLS FOR PEST PROTECTION VIA GENE SILENCING | Final Rejection | Tropic Biosciences UK Limited |
| 18001244 | CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18289921 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | Final Rejection | UNIVERSITÉ D'AIX-MARSEILLE |
| 17266995 | METHODS FOR ASSESSING INTEGRATED NUCLEIC ACIDS | Non-Final OA | Juno Therapeutics, Inc. |
| 18266135 | RNA MANUFACTURING | Non-Final OA | BioNTech SE |
| 18276010 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING MPS VI DISEASE | Non-Final OA | SIGILON THERAPEUTICS, INC. |
| 16499449 | SYSTEMS AND METHODS FOR PREDICTING AND MONITORING CANCER THERAPY | Non-Final OA | PREDICINE, INC. |
| 17405706 | PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES | Final Rejection | Roche Innovation Center Copenhagen A/S |
| 18328561 | COMPOSITIONS AND METHODS FOR PRODUCING OREXIN NEUROPEPTIDE USING NANOCAPSULE-BASED DRUG DELIVERY SYSTEM | Non-Final OA | VL Biotech Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy